Pinfenon (S) (R) – First Patent for Canine Cardiac Disorder Treatment

Scarecrow Incorporated, located in Tokyo’s Shibuya Ward, has successfully acquired the world’s first patent for its animal supplement, Pinfenon (S) (R). This innovative product is designed to treat and prevent cardiac disorders in dogs by lowering the levels of atrial natriuretic peptide (ANP). The patent also covers the manufacturing methods for this unique treatment and prophylactic drug.

Key Points

Patent Overview

• Name of Invention: Treatment and prophylactic drug for lowering ANP in dogs and manufacturing methods.
• Patent Registration Number: P7542838.
• Patent Registration Date: August 23, 2024.
• Patent Holder: Scarecrow Incorporated.
• Inventors: Hiroshi Okawa, Hiroshi Koie.
• Application Date: February 15, 2024.

Product Description

• Pinfenon (S) (R): A supplement that reduces the ANP biomarker, associated with mitral regurgitation and other heart conditions in dogs.
• Key Ingredient: Extracted from French maritime pine bark, known for its high physiological activity.
• Supporting Ingredients: Fermented sesame extract and yeast extract.
• Form: 5mm tablets for ease of oral administration.

Clinical Study

Study Sample: 27 dogs with mitral regurgitation across 15 hospitals in Japan.

Study Duration: 30 days.

Results

• Significant decrease in ANP levels, showing improvement in heart health.
• Notable improvement in symptoms, such as difficulty breathing.
• Clinical tests demonstrated effectiveness with dogs receiving Pinfenon (S) (R) alongside their existing cardiac medication.

Disease Targeted

• Mitral Regurgitation: A common cardiac disorder in small dogs, especially prevalent in Japan, where valvular diseases are the third leading cause of death in elderly dogs.
• Biomarker: ANP, a hormone secreted by the heart’s atrium, acts as a key indicator of cardiac disorders and is used in diagnosing the severity of mitral regurgitation.

Scientific Backing

Research Support

• Over 800 research papers globally, supporting the high efficacy of the active ingredient, Pycnogenol, which is derived from the bark of the French maritime pine.

Historical Clinical Data

• Pinfenon (S) (R) has previously shown positive effects in studies on canine heart disorders, including previous findings published in journals such as Companion Animal Practice (CAP).

Product Applications

• Pinfenon (S) (R) is not only useful as a treatment drug but also as a prophylactic drug to prevent cardiac issues in susceptible dogs.
• The supplement is part of a broader range of products, which could also include food, shampoos, and essences.

Regulatory Approval

Japan Patent Office Approval

• Pinfenon (S) (R) is officially recognized as a treatment drug in Japan, opening avenues for broader commercial applications and distribution.

Summary/Static	Details
Why in the news?	Pinfenon (S) (R) – First Patent for Canine Cardiac Disorder Treatment
Patent Name	Treatment and prophylactic drug for lowering ANP in dogs and manufacturing methods
Patent Number	P7542838
Patent Holder	Scarecrow Incorporated
Inventors	Hiroshi Okawa, Hiroshi Koie
Main Ingredient	French maritime pine bark extract (Pycnogenol), fermented sesame extract, yeast extract
Form	5mm tablets
Target Disease	Mitral regurgitation (common in small dogs)
Biomarker	Atrial natriuretic peptide (ANP), key heart health indicator
Clinical Study	– 27 dogs with mitral regurgitation – Duration: 30 days – Results: Significant decrease in ANP, improvement in breathing difficulty
Regulatory Approval	Approved as a drug by the Japan Patent Office
Product Applications	Also applicable in food, shampoos, and essences for canine cardiac health